Pfizer mRNA Vaccine Shows Strong Protection (anti-Spike Antibody) in Healthcare Workers in 1,000-Bed Myanmar Hospital

Khin Phyu Pyar Professor and Head/ Senior Consultant Physician, Department of Medicine/Nephrology, Defense Services Medical Academy/ No. (1) Defense Services General Hospital in Yangon, Myanmar and colleagues conducted an analytic study at the 1,000-bed Defense Services General Hospital in 2024. SARSCoV-2 antibody level was measured twice; prior to COVID-19 mRNA Vaccine and 70 days after vaccination. The team collected data using standardized forms to help aggregate data for the analysis. Why this study? With a dynamic, mutating virus, the Pfizer-BioNTech COVID-19 mRNA Vaccine (nucleoside modified) tozinameran was available in Myanmar in January 2024. This study aimed to assess changes in SARSCoV-2 antibody level in healthcare workers (HCW) following COVID-19 mRNA Vaccine and to determine the factors influencing antibody response. The authors report that healthcare worker (HCW) participants had acquired immunity to SARSCoV-2 virus in January 2024. Their SARSCoV-2 antibody level doubled on Day ‘70’ after one dose of (Comirnaty) COVID-19 mRNA Vaccine (nucleoside modified) tozinameran. Among the study cohort, the younger age group, females, those HCW’s without comorbid disease, those with normal weight and overweight group, and  presence of COVID symptoms at the time of vaccination had better antibody response. Antibody response was not related with history of COVID-19 in past 6 months to 1 year. One dose of COVID-19 mRNA Vaccine was 100% effective in promoting anti-Spike antibody.

A compelling result, outcomes were published in the International Journal Of Medical Science And Clinical Research Studies.